That Remicade/Enbrel (most notably Enbrel) will be serious competitor to DNA/BGEN new psoriasis drug was very predictive 12 months ago. Again, surprise hit street. And BGEN rise 2 points???
Friday February 22, 9:15 am Eastern Time
Press Release
SOURCE: Robert Wood Johnson Medical School
Positive Results From ENBREL(R) (etanercept) Monotherapy Psoriasis Study to be Presented by RWJMS Researcher at American Academy of Dermatology Conference
NEW BRUNSWICK, N.J., Feb. 22 /PRNewswire/ -- Alice Gottlieb, MD, Ph.D., Professor of Medicine at the University Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School, will present results from a Phase 2 clinical study of ENBREL® (etanercept) for the treatment of psoriasis at the 60th Annual American Academy of Dermatology Conference in New Orleans. The study demonstrated that 56% of patients treated with ENBREL had at least a 75% improvement in their psoriasis over the six month period compared to 5% of patients receiving placebo. ENBREL was approved by the U.S. Food and Drug Administration (FDA) last month to treat psoriatic arthritis a disease with both joint and skin involvement.
``We previously have seen the effectiveness of ENBREL on the psoriatic plaques of psoriatic arthritis patients,'' said Gottlieb. ``This new psoriasis study provides data that show ENBREL, used without other medicines, may be a powerful new weapon against this life-impacting disease.''
Patients treated with ENBREL in this study experienced a significant improvement at 3 months, with 30 % of patients on ENBREL achieving PASI 75, compared with 2% of those on placebo (p < 0.0001). Continued improvement was seen throughout the study. After six months of treatment, 56% of patients receiving ENBREL achieved PASI 75, compared with 5% of those receiving placebo at six months. Additionally, 21% of patients receiving ENBREL achieved PASI 90 compared to none of the patients who received placebo. <snip> |
